Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessPublished version of a preprint
The DOI matches its Crossref record; 331 of the 348 references it cites were found in a registry or an index; 216 of the 381 sources its claims cite were checked for support.
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.
Overview
CoChat Summary
TL;DR
This 2022 ADA/EASD consensus report updates person-centered management of hyperglycemia in nonpregnant adults with type 2 diabetes, emphasizing holistic care, weight management, physical activity, DSMES, and individualized medication selection. It gives strongest priority to GLP-1 receptor agonists and SGLT2 inhibitors for people with established or high-risk cardiovascular, kidney, or heart failure disease, based on evidence synthesized from trials and meta-analyses published through 13 June 2022.
Key findings
- A PubMed search identified randomized controlled trials, systematic reviews, and meta-analyses published in English between 28 January 2018 and 13 June 2022; the report built on the 2012, 2015, 2018, and 2019 consensus statements.
- In a network meta-analysis of 453 trials across nine drug classes, the greatest HbA1c reductions were seen with insulin regimens and GLP-1 RA; subcutaneous semaglutide had the greatest body-weight reduction, and SGLT2i and GLP-1 RA had the greatest blood-pressure reductions.
- In comparative effectiveness analyses, SGLT2i were superior to GLP-1 RA for reducing heart failure hospitalization and a composite kidney outcome, while GLP-1 RA appeared more efficacious for stroke; no important differences were evident for mortality or other cardiovascular outcomes.
- The report states that DSMES significantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective; it also reports specific trial effects such as STEP 2 weight loss of 9.6% with semaglutide 2.4 mg, and AWARD-11 and SUSTAIN FORTE showing greater HbA1c and weight reductions with higher-dose GLP-1 RA.
Methods
- Consensus report written by an ADA/EASD panel, using prior consensus reports as the starting point and incorporating evidence from publications since 2018.
- Evidence source: PubMed search for English-language RCTs, systematic reviews, and meta-analyses published between 28 January 2018 and 13 June 2022, plus reference-list screening for additional studies.
- Evidence appraisal: papers were grouped by topic, subgroup meta-analyses were assessed for credibility using relevant guidance, and recommendations were informed by GRADE; draft recommendations were reviewed by invited reviewers and opened for public comment.
Limitations
- The paper states that subgroup analyses should not be regarded as conclusive and should be formally appraised and ideally complemented by relevant RCTs.
- The text notes that evidence is limited for some populations because of underrepresentation in trials, including younger people, older adults, women, and non-White participants; this is an evident limitation of generalizability.
- The report also makes evident that some conclusions rely on network meta-analyses, observational data, and nonrandomized studies, and that some outcomes (e.g., long-term cardiovascular profile of tirzepatide) were still pending, which limits certainty.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
140 Valid · 9 Not valid · 61 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
What the sources say
- Not checked — no full text of the sourcecites [223] Tsapas, 2020, Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis, Ann Intern Med source
- Disputedcites [259] Palmer, 2021, Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials, BMJ sourceExperimental — accuracy not yet measured
The Results > Outcomes section reports fewer non-fatal myocardial infarctions with both drug classes in low-risk patients and fewer non-fatal strokes with GLP-1 receptor agonists. That contradicts the claim that no drug class benefits cardiovascular events in this group. The Discussion > Clinical uncertainties section cautions that trials generally did not include the lowest-risk patients and does not judge whether the absolute effects are clinically notable. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“As with any laboratory test, HbA1c measurement has limitations (2,52).”
What the sources say
- Supportedcites [2] Draznin, 2022, 6. Glycemic targets: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The “A1C Limitations” section (p. 2) explicitly says the A1C test is subject to limitations and that its measurement varies, as with any laboratory test. (LLM, conf=0.95)
- Supportedcites [52] American Diabetes Association Professional Practice Committee, 2022, 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The Fasting and 2-Hour Plasma Glucose section explicitly refers to “these limitations with A1C,” including lower diagnostic sensitivity and imperfect correlation with average glucose in some individuals. The Race/Ethnicity/Hemoglobinopathies section also notes that hemoglobin variants can interfere with A1C measurement. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, these multifaceted domains (heterogeneity across individual characteristics, social determinants of health, and psychosocial factors) challenge individuals with diabetes, their families, and their providers when attempting to integrate diabetes care into daily life (49).”
What the sources say
- Supportedcites [49] Young-Hyman, 2016, Psychosocial care for people with diabetes: a position statement of the American Diabetes Association, Diabetes Care source
The Introduction says complex environmental, social, behavioral, and emotional factors challenge people with diabetes and their families as they integrate care into daily life. Life Course Considerations identifies social determinants and person-based characteristics as factors providers should consider, while the Conclusions describes challenges to providing that care. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Type 2 diabetes is a very heterogeneous disease with variable age at onset, related degree of obesity, insulin resistance, and tendency to develop complications (39,40).”
What the sources say
- Supportedcites [39] Ahlqvist, 2018, Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, Lancet Diabetes Endocrinol source
The Abstract describes type 2 diabetes as highly heterogeneous and identifies age at diagnosis, BMI, and insulin resistance as clustering variables. It reports that the resulting clusters differed in patient characteristics and risk of complications, supporting the claimed variation. (LLM, conf=0.92)
- Supportedcites [40] Pigeyre, 2022, Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial, Diabetologia source
The Introduction describes heterogeneity in diabetes presentation and progression. The Results identify subgroups differing in age at diagnosis, BMI and insulin-resistance-related characteristics; the Abstract reports differences in renal outcomes between subgroups. Together, these passages support the cited statement about variation among people with type 2 diabetes. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High-quality evidence has consistently shown that DSMES signi fi cantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective (22,25 -30).”
What the sources say
- Not checked — no full text of the sourcecites [22] Draznin, 2022, 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes–2022, Diabetes Care source
- Partly supportedcites [25] Chrvala, 2016, Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control, Patient Educ Couns sourceExperimental — accuracy not yet measured
The Introduction says evidence from randomized and observational studies suggests DSME is cost-effective. The citing sentence presents cost-effectiveness as a consistently demonstrated finding, whereas this review does not establish it; Practical implications says DSME must be cost-effective, not that the review found it to be so. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [26] Pillay, 2015, Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis, Ann Intern Med source
- Not checked — no full text of the sourcecites [27] Zhao, 2017, Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, J Adv Nurs source
- Partly supportedcites [28] Odgers-Jewell, 2017, Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression, Diabet Med sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) says group-based education for people with type 2 diabetes may be more cost-effective than individual education because it requires less time and funding. That qualified comparison does not establish the broader, unqualified claim that DSMES is cost-effective. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [29] He, 2017, Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis, Endocrine source
- Not checked — no full text of the sourcecites [30] Chatterjee, 2018, Diabetes structured self-management education programmes: a narrative review and current innovations, Lancet Diabetes Endocrinol source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
127 more claims · 71 with their cited sources checked
Create a free account to see all 237 claims and every source verdict.
- It may state two separate claims as one. 88
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The DiRECT dietary intervention was highly costeffective and deliverable in primary care. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“thus cost-savings might be greater. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as first-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal benefits [109].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may be particularly important in young-onset T2D where higher rates of obesity, more rapid deterioration in blood glucose levels and earlier development of diabetes complications have been observed [9,95].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increase insulin secretion regardless of glycemia, typically resulting in 2–3 kg weight gain [44].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [44]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Decision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 20×
“Notably, the benefits of GLP-1 RA and SGLT2i for cardiovascular and renal outcomes have been found to be independent of metformin use, and thus these agents should be considered in people with established or high risk of CVD, HF, or CKD, independent of metformin use (173–175).”
BackgroundInfluential
Research works printed but not linked: 2
- Nathan, Glycemic outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study, N Engl J Med
- Nathan, Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes, N Engl J Med
Cited by
Items 1,601–1,700 of 2,053
Yagi, K., Chujo, D., Ogawa, S., et al. (2025) · Case Reports in Medicine · doi:10.1155/carm/2871380
“Early identifcation of LVDD is clinically meaningful, as it in-forms therapeutic decisions, including the selection of antidiabetic agents with proven efcacy in preventing heart failure progression [14].”
Dubey, V. P., Kansagra, J. J., Kamani, B. K., & Sureja, V. P. (2025) · World Journal of Experimental Medicine · doi:10.5493/wjem.v15.i3.108467
Duration of DKA and Insulin Use in People with and Without SGLT2 Inhibitor Medications
Park, Y., Lee, A. K., Barmanray, R., Gao, F. M., Fourlanos, S., & Gilfillan, C. P. (2025) · Medicines · doi:10.3390/medicines12030021 · Cited by 1
“Key consensus international guidelines recommend SGLT2i use in people with T2D who have established cardiovascular or kidney disease or multiple risk factors for cardiovascular disease [2,3].”
Ajayi, T. O., Ogundeji, J. J., & Ajayi, A. M. (2025) · Clinical Phytoscience · doi:10.1186/s40816-025-00401-5
“In addition, body weight was also reduced in rats fed with HFD. Early reports had indicated that weight reduction is associated with better glucose levels, especially in type 2 diabetes which is usually accompanied by lowering glycosylated hemoglobin (HbA1c) levels [55, 57].”
Hypoglycemia in Type 2 Diabetes: A Survey of Physicians from Three Developing Regions
Beshyah, S. (2025) · Libyan International Medical University Journal · doi:10.1055/s-0045-1811230
Alqahtani, N. S., & Alenezi, A. (2025) · Current Research in Nutrition and Food Science Journal · doi:10.12944/crnfsj.13.2.7
Modern Machine Learning Approaches for Predicting Type 2 Diabetes Mellitus
Butkova, T. V., Kulikova, L. I., Malsagova, K. A., Petrovskiy, D. V., Rudnev, V. R., Анатольевна, Р. Е., Kulikov, A. V., & Kaysheva, A. L. (2025) · Mathematical Biology and Bioinformatics · doi:10.17537/2025.20.301
Ma, X., Chattopadhyay, K., Xu, M., Li, L., & Li, J. (2025) · JMIR mhealth and uhealth · doi:10.2196/65919 · Cited by 2
“T2DM clinical practice guidelines recommend adequate glycemic control, aiming for a fasting blood glucose level of 7 mmol/L and glycosylated hemoglobin (HbA 1c ) level of 7% in most patients [7,8].”
Cokro, F., Sauriasari, R., Tahapary, D. L., & Setiawan, H. (2025) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01544-4
“Both SGLT2 inhibitors and sulfonylureas are recommended as second-line therapy when added to metformin, according to many guidelines [10], and sulfonylureas are commonly chosen as an alternative to metformin add-on therapy [11].”
Han, Y.-N., Wang, T., Lin, Q., Li, C., & Ren, Y. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1662140
Gestione del diabete nei pazienti con tumore neuroendocrino tra nuovi e “vecchi” farmaci
Ruggeri, R. M., Grossrubatscher, E. M., Ciocca, E., et al. (2025) · L Endocrinologo · doi:10.1007/s40619-025-01683-0
“In caso di scarso controllo glicemico nonostante la titolazio-ne dell’insulina basale, andrebbe implementato il regime basal-bolus con l’aggiunta dell’insulina pre-prandiale [15].”
InfluentialAdvances in SGLT2 Inhibitors for Cardiovascular Diseases
员, 峰. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1592519
Balancing Benefit and Risk: Continuing Tirzepatide after Allergic Reactions
Beshyah, S. (2025) · Ibnosina Journal of Medicine and Biomedical Sciences · doi:10.1055/s-0045-1811649 · Cited by 1
Executive summary of the document ‘Diabetes Day Hospital. Value proposition’
Martín, F. J. E. S., Lesmes, I. B., Peralta, F. G., et al. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2025.501601
Lee, B., Lee, C. B., Lim, S. K., Kim, S. G., Kim, N. H., Won, J. C., Lee, W. J., Kang, M. J., Yuh, J. Y., Du, L. Y., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70111 · Cited by 1
Young, K., McGovern, A. P., Hopkins, R., Jansz, T. T., Cardoso, P., Holman, R. R., Pearson, E. R., Hattersley, A. T., Jones, A. G., Docherty, K. F., et al. (2025) · medRxiv · doi:10.1101/2025.09.08.25335314
Agrawal, M. B., Ahluwalia, A. I., Boddula, R., Baidya, A., Saikia, H., Mathew, A., Naryanan, P., Arjun, R., Reddy, M., Kesarkar, R. N., et al. (2025) · Cureus · doi:10.7759/cureus.92594
“…weight management as a primary treatment goal alongside glycemic management for overweight T2DM patients and recognized the benefits of 3%-7% baseline weight reduction, aligning with ADA and EASD recommending a 5% target, noting that >10% weight loss early in T2DM increases remission chances [30].”
Real-world effectiveness of sodium glucose transporter 2 inhibitors among youth with type 2 diabetes
Timkovski, M., Patel, D., Brown, E. A., Magella, B., SHAH, A. S., & Wolf, R. M. (2025) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2025-0243 · Cited by 1
Diabetic-Induced Nephropathy and Its Mitigation by Algae
Akkara, P. J., Vinnakota, Y. Y., Esther Shoba, R., & Angeline, M. S. (2025) · Springer eBooks · doi:10.1007/978-981-95-0571-5_8
Clinical Trials and Patents Related to Anti-diabetic Properties of Algae
Esther Shoba, R., Ramachandran, D., & Angeline, M. S. (2025) · Springer eBooks · doi:10.1007/978-981-95-0571-5_13
Insights Into the Management of Type 2 Diabetes at Diagnosis in Spain: The NEW2TYPE2 Study
García‐Prieto, C. F., Peralta, F. G., Villar‐Taibo, R., Cinza‐Sanjurjo, S., Redondo‐Antón, J., Díaz‐Cerezo, S., & Santos, M. R. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70095
“Guidelines indicate that less rigorous HbA1c targets should be considered for people with severe comorbidities or advanced CVD [2, 8], and stricter ones (HbA1c 6.5”
InfluentialAlgae to the Rescue: Unveiling the Potential Role of Neuroprotection in Diabetic Neuropathy
Kathirvel, M. (2025) · Springer eBooks · doi:10.1007/978-981-95-0571-5_7
Song, L., Bai, H., Pan, Y., Zhang, L., Luo, A., Long, Z., Dai, L., & Liao, L. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-108373
Beyond boundaries: exploring the latest guidelines for diabetes and cardiovascular health
Ruszala, V., & Williams, R. (2025) · Practice Nursing · doi:10.12968/pnur.2025.0087
Targets for glycemic control and its monitoring
Moriconi, D., & Nannipieri, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00283-1
Das, S., Ramachandran, A., Wangnoo, S., Deb, P., Kadam, Y., Pednekar, A., & Kesarkar, R. N. (2025) · Cureus · doi:10.7759/cureus.93632 · Cited by 1
“Hence, careful selection of glucose-lowering agents is vital for reducing long-term diabetes-related complications [5].”
Vega-García, S., Rivero-García, E., Villarreal-Avalos, M. G., Islas-Salinas, C., Ortíz, G. O., & López, L. V. (2025) · Atención Familiar · doi:10.22201/fm.14058871p.2025.4.92997
Vega-García, S., Rivero-García, E., Villarreal-Avalos, M. G., Islas-Salinas, C., Ortíz, G. O., & López, L. V. (2025) · Atención Familiar · doi:10.22201/fm.14058871p.2025.4.92998 · Cited by 1
Alawadi, F., Jabbar, A., Fiad, T. M., Hafidh, K., Hassanein, M., Tangı, F., Rai, S., Tebbs, K. W., Harrison, L., & Isailovic, T. V. (2025) · Dubai Diabetes and Endocrinology Journal · doi:10.18502/ddej.v31i1.19920
“American and European guidelines recommend a glycated hemoglobin (HbA1c) target of 7.0% ( 53 mmol/mol) for most nonpregnant adults [3, 8, 9].”
InfluentialWeekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes
Samajdar, S. S., Joshi, S. R., & Mukherjee, S. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2511881
Lifestyle in the glycemic management of type 2 diabetes
Poulia, K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00297-1
Coordination Chemistry of Diabetes‐Associated Islet Peptide Hormones
Pi, Y., Jung, H., & Han, J. (2025) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.202500407 · Cited by 1
Peña, E., Inatti, A., Taly, A., et al. (2025) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2025.1310027
Choong, I., & Idris, I. (2025) · Springer eBooks · doi:10.1007/978-981-97-7640-5_45
Hadjiconstantinou, M., Trevena, P., Schreder, S., Bodicoat, D. H., & Davies, M. J. (2025) · Patient Education and Counseling · doi:10.1016/j.pec.2025.109401
Self-citationHussein, H. Q., Haji, H., & MUSTAFA, M. D. M. Z. A. R. A. K. (2025) · Health Problems of Civilization · doi:10.5114/hpc.2025.155551
Piatti, A., Borghese, R., Perino, G., Bellelli, S., Rivoiro, C., Tassone, F., Romeo, F., Doglio, M., Ioli, G. M., & Giorda, G. B. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02602-3
Pawar, A. D., Rohile, S. B., & D., S. S. (2025) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-29628
Nagarajappa, S. M., Dayananda, G., Varatharajan, S., Ilangovan, S., & Velan, S. S. (2025) · The Journal of Medical Sciences · doi:10.5005/jp-journals-10045-00426
Lian, D., Liu, J., Wei, Y., Yang, Y., Ren, Y., Bao, S., Liu, L., Liu, S., & Chen, Y. (2025) · Patient · doi:10.1007/s40271-025-00776-0
“Aligned with American Diabetes Association/European Association for the study of Diabetes guidance on person-centered care, structured preference information can help frame option discussions around what matters most to patients [52].”
A comparative study of serum levels of glucose and aggression: A cross-sectional study
Çavdar, V. C., & Akbaş, F. (2025) · Medicine · doi:10.1097/md.0000000000045280
“[3,4] Studies have shown that the quality of life in patients with diabetes varies depending on their blood glucose regulation and the presence of diabetes-related complications.”
Termannsen, A., Bjerre, N., Hansen, G. S., Jalking, L., Færch, K., Hempler, N. F., Quist, J. S., & Varming, A. R. (2025) · Pilot and Feasibility Studies · doi:10.1186/s40814-025-01715-4
Neuperdt, L., Du, Y., Nübel, J., Hapke, U., Walther, L., Mensink, G., Richter, A., Scheidt‐Nave, C., Baumert, J. J., & Heidemann, C. (2025) · PLoS ONE · doi:10.1371/journal.pone.0336019
“Clinical guidelines endorse routine assessment and management of psychosocial problems in people with diabetes [85–87].”
Early glycemic control and subsequent risk of incident dementia among new metformin users
Power, M. C., Madsen, M., Bødkergaard, K., Zimmerman, S. C., Ackley, S. F., Gilsanz, P., Glymour, M. M., Henderson, V. W., Sørensen, H. T., & Thomsen, R. W. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.10.017 · Cited by 4
Syaripudin, A., & Lameky, V. Y. (2025) · Multidisciplinary Science Journal · doi:10.31893/multiscience.2026223
Sun, R., Wang, Y., Shu, H., Li, L., Yao, J., Su, X., Shi, B., Wu, C., Ma, J., & WANG, Q. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70262 · Cited by 1
Pharmacologic Therapy for Type 2 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch04
Pharmacologic Therapy for Type 1 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch01
Kimura, K., TAKAGI, Y., Harada, M., Ueda, S., Minamisawa, M., Sonoda, K., Oiwa, A., Yazaki, Y., Sakurai, S., Tomita, T., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01822-8
“Therefore, in addition to glycemic control, strategies to prevent renal and cardiovascular complications are essential for managing type 2 diabetes [1].”
Pallarés‐Carratalá, V., Ruiz‐García, A., Segura‐Fragoso, A., Escobar, C., Cervera-Pérez, M. I., Alonso-Moreno, F. J., Arranz-Martínez, E., Barquilla-García, A., Aldana, D. R., García, J. P., et al. (2025) · Medicina · doi:10.3390/medicina61122087
“Traditional guidelines suggest starting most T2D patients on metformin, adding a second antidiabetic drug if HbA1c goals aren’t met, and introducing a third if needed for further control [9,10].”
The Safety, Efficacy, and Clinical Use of Novel Once-Weekly Insulins in the Management of Diabetes
DeLuca, A., Schultz, A., Ofori, H., Maggio, V., Rizzo, M., & Rizvi, A. A. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2593372 · Cited by 1
“Current guidelines for the treatment of T2D recommend lifestyle modifications along with oral glucose-lowering medications and injectable non-insulin agents as initial pharmacotherapeutic options based on patient-specific characteristics [5,6].”
EndoCompass Project: Research Roadmap for Diabetes, Obesity, and Metabolism
Mathieu, C., Meireles, M., Pagotto, U., Wabitsch, M., Banerjee, I., Bartolomé, A., Battelino, T., Beck, J., Chiarelli, F., León, D. D. D., et al. (2025) · Hormone Research in Paediatrics · doi:10.1159/000549194 · Cited by 1
“Therefore, according to the majority of the current guidelines, the control of body weight represents one of the most important directions for the successful prevention and treatment of T2D [137].”
Self-citationRasmussen, L., Andersen, J. H., Kofoed‐Enevoldsen, A., Jensen, P. B., Madsen, G. K., Jűrgens, G., Pottegård, A., & Andersen, S. E. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70343
Bennett, K. A., Gouleguine, R., Sutherland, C. D., & Savage, A. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117575
Lemma, D. A., Billoro, B. B., Wolde, A., Wallie, B. Y., Ganamo, E. G., Ayalew, F., & Lorato, S. S. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00250-8 · Cited by 4
“Consequently, international guidelines from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) consistently recommend a target HbA1c level of below 7.0% (53 mmol/mol) for most non-pregnant adults [10–12].”
InfluentialCardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes
Bonnesen, K., Heide‐Jørgensen, U., Christensen, D. H., Lash, T. L., Pedersen, L. H., Thomsen, R. W., Matthews, A., & Schmidt, M. (2025) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70276 · Cited by 1
Driessens, H., Woldring, J. A. C., Nijkamp, M. W., van Dijk, P. R., & Klaase, J. M. (2025) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2025.100426
“[27].”
Kitsunai, H., Nanbu, T., Maruyama, F., Sato, T., Takiyama, Y., Sasaki, T., Shukuda, Y., Takiyama, T., Kurigaki, A., Takiyama, Y., et al. (2025) · Trials · doi:10.1186/s13063-025-09309-4 · Cited by 1
“…report, “Man-agement of Hyperglycemia in Type 2 Diabetes Mellitus 2022,” recommended multiple drug treatment options for the treatment of T2D, considering individual glycemic and weight goals, the risk of hypoglycemia, diabetes complications such as cardiovascular and renal diseases, and costs [2].”
Parsonage, I., Wainwright, D. W., & Barratt, J. (2025) · BMC Family Practice · doi:10.1186/s12875-025-03116-1 · Cited by 1
Oshakbayev, K., Durmanova, A., Bikhanov, N., Nabiyev, A., Suleimenov, T., Idrisov, A., Daniyarova, G., Kurgambekova, D., Sagimbayeva, M., & Kuttymuratov, G. (2025) · Research Square · doi:10.21203/rs.3.rs-8096250/v1
Metformin alleviates diastolic dysfunction in mice with experimental diabetic cardiomyopathy
Chan, J. S. F., Dakhili, S. A. T., Wu, N. R., Stenlund, M. J., King, A. N., Dong, L., Mangra-Bala, I. A., Shafaati, T., Ferrari, S. R., Greenwell, A. A., et al. (2025) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2025.100825 · Cited by 3
“Metformin is a biguanide and first-line therapy of choice in the management of glycemia in people living with T2D [12], which induces glucose-lowering by suppressing hepatic glucose production, either via an adenosine monophosphate-activated protein kinase (AMPK)-dependent or AMPK-independent…”
Hassanein, M. M., Alessa, T., Hafidh, K., Alzubaidi, L. M. Y., Jallo, M. K. I., Slail, F. Y. A., Elbadawi, H., & Malik, R. A. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01824-6
“…agents is GLP-1 RAs which are particularly beneficial for individuals with obesity, established atherosclerotic cardiovascular disease (ASCVD), or chronic kidney disease (CKD), due to their favorable effects on weight, glycemic control, cardiovascular (CV) and renal outcomes [11, 37].”
Sethi, B. K., Mehta, A., Dasgupta, A., Chawla, M. S., Deka, N., Agarwal, N., Mazumder, C., Ghosh, I., Gala, V., Muchhala, S., et al. (2025) · Cureus · doi:10.7759/cureus.99023
“Reflecting this, the 2022 ADA/EASD consensus recommends SGLT2 inhibitors as first-line agents in high-risk patients, even before metformin [36].”
Kim, H. S., Kim, M., Kim, H. S., Cho, Y. K., Jung, C. H., & Lee, W. J. (2025) · Clinical Endocrinology · doi:10.1111/cen.70078
Chen, L., Lv, L., Zhang, Z., & Jiang, S. (2025) · Actas Urológicas Españolas · doi:10.1016/j.acuro.2025.501901
Łagowski, R., Kosęda, J., Juniewicz, H., Kudlińska, Z., Heryć, P., Kananowicz, K., Laska, Z., Latour, M., Jędrasiak, A., & Piotrowski, J. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4249
He, L., Zheng, W., Li, Z., Chen, L., Kong, W., & Zeng, T. (2024) · Figshare · doi:10.6084/m9.figshare.26572897
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648916
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648943
Mohammedi, K., Fauchier, L., Quignot, N., Khachatryan, A., Banon, T., Kapnang, R., Kikuchi, K., Ren, H., Massien, C., Vigié, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25929062
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648934
Brierley, M. L., Chater, A., Edwardson, C. L., Castle, E. M., Hunt, E. R., Biddle, S., Sisodia, R., & Bailey, D. P. (2024) · Figshare · doi:10.6084/m9.figshare.25687423
Csatordai, M., Benkő, R., Matúz, M., Engi, Z., Csupor, D., Lengyel, C., & Doró, P. (2024) · Figshare · doi:10.6084/m9.figshare.26711594
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648922
Ahmad, A., & Sabbour, H. M. (2024) · Figshare · doi:10.6084/m9.figshare.26695041
Wang, P., Zhang, Y., Xu, W., He, J., Peng, L., Feng, Y., Xu, P., Chong, W., Hai, Y., Jia, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24940445
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648949
Brierley, M. L., Chater, A., Edwardson, C. L., Castle, E. M., Hunt, E. R., Biddle, S., Sisodia, R., & Bailey, D. P. (2024) · Figshare · doi:10.6084/m9.figshare.26711456
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648931
Dubey, V. P., Kansagra, J. J., Sureja, V., & Kheni, D. (2024) · Figshare · doi:10.6084/m9.figshare.26686359
Brierley, M. L., Chater, A., Edwardson, C. L., Castle, E. M., Hunt, E. R., Biddle, S., Sisodia, R., & Bailey, D. P. (2024) · Figshare · doi:10.6084/m9.figshare.25687597
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648940
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648946
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648919
Additional file 1 of Diabetes and osteoporosis: a two-sample mendelian randomization study
Qu, Y., Zhu, Z.-H., Li, J.-X., Zhang, W., Chen, Q., Xia, C.-L., Ma, J.-N., Ou, S., Yang, Y., Qi, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25678508
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648913
Csatordai, M., Benkő, R., Matúz, M., Engi, Z., Csupor, D., Lengyel, C., & Doró, P. (2024) · Figshare · doi:10.6084/m9.figshare.26711591
Wang, P., Zhang, Y., Xu, W., He, J., Peng, L., Feng, Y., Xu, P., Chong, W., Hai, Y., Jia, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24940868
Brierley, M. L., Chater, A., Edwardson, C. L., Castle, E. M., Hunt, E. R., Biddle, S., Sisodia, R., & Bailey, D. P. (2024) · Figshare · doi:10.6084/m9.figshare.26711453
Brierley, M. L., Chater, A., Edwardson, C. L., Castle, E. M., Hunt, E. R., Biddle, S., Sisodia, R., & Bailey, D. P. (2024) · Figshare · doi:10.6084/m9.figshare.26711450
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648928
Wang, P., Zhang, Y., Xu, W., He, J., Peng, L., Feng, Y., Xu, P., Chong, W., Hai, Y., Jia, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26659708
Csatordai, M., Benkő, R., Matúz, M., Engi, Z., Csupor, D., Lengyel, C., & Doró, P. (2024) · Figshare · doi:10.6084/m9.figshare.26711588
Liu, J., Chang, X., Ding, X., He, X., Wang, J., & Wang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26648925
He, L., Zheng, W., Li, Z., Kong, W., & Zeng, T. (2023) · Figshare · doi:10.6084/m9.figshare.22599004
Ono, R., Ogami, C., Hasegawa, C., To, H., Matsumoto, Y., & Tsuji, Y. (2023) · Figshare · doi:10.6084/m9.figshare.24779192
Zhou, J., Zheng, Y., Xu, B., Long, S., Zhu, L.-E., Liu, Y., Li, C., Zhang, Y., Liu, M., & Wu, X. (2024) · Figshare · doi:10.6084/m9.figshare.26680684
Ahmad, A., & Sabbour, H. M. (2024) · Figshare · doi:10.6084/m9.figshare.26695038
He, L., Zheng, W., Li, Z., Chen, L., Kong, W., & Zeng, T. (2024) · Figshare · doi:10.6084/m9.figshare.26572894
Nicholls, S. J., Tofé, S., le Roux, C. W., D’Alessio, D. A., Wiese, R. J., Pavo, I. J., Brown, K. E., Weerakkody, G. J., Zeytinoglu, M., & Romera, I. (2024) · Figshare · doi:10.6084/m9.figshare.25201920
Metadata
- Authors
- Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B.
- Affiliations
- University of Leicester (GB)
- Brigham and Women's Hospital (US)
- National Heart, Lung, and Blood Institute (US)
- American Diabetes Association (US)
- Duke University (US)
- Johns Hopkins University (US)
- Joslin Diabetes Center (US)
- 9Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- KU Leuven (BE)
- Università Cattolica del Sacro Cuore (IT)
- University of Copenhagen (DK)
- Medical University of Sofia (BG)
- 17Diabetes Centre, Clinical Research and Evidence-Based Medicine Unit, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Buse, John B.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-09-28
- Volume
- 45
- Issue
- 11
- Pages
- 2753-2786
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC10008140
- OpenAlex
- W4296802076
- Cited by
- 2,104
- References
- 348
- Citations by year
- 2026: 500 · 2025: 567 · 2024: 509 · 2023: 396 · 2022: 50
- FWCI
- 282.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- European Association for the Study of Diabetes
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, glycemic targets, social determinants of health, physical activity, sleep, weight management, SGLT2 inhibitors, GLP-1 receptor agonists, cardiorenal protection, cardiovascular outcomes, renal outcomes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adult, Diabetes Mellitus, Type 2, Europe, Humans, Hyperglycemia, Hypoglycemic Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.